Innovation Pharmaceuticals Inc (IPIX)

[Orion Nebula]

Following the initial release of data for the B UP phase 2 there were posters who stated there was no indication of a dose dependent response. Their assertion was based on the Primary Efficacy endpoint of Clinical Remission where both Cohort A and Cohort B had similar results (both cohorts reporting 3/6 patients as having met this endpoint).

The study is based on small numbers, not powered for statistical significance and was set up for proof of concept. With those caveats in mind, when examining the efficacy data for the secondary endpoints there are hints of a dose dependent response. The Full MMDAI data indicates a 50-75% reduction in 2 patients in cohort A and in 4 patients in Cohort B. In the Partial MMDAI there was a 50-83% reduction in 2 patients in Cohort A and 3 Patients in Cohort B. In the Patient Quality of Life Measure, 3 of 6 patients reported significant improvements while in cohort B 5 of 6 patients did.

To me these results do not establish a solid basis for saying there is dose dependent response. But I sure like the direction the results are pointing rather than no divergence between the results of the two groups. It will bear watching if the results of these measures diverge even more when the results of Cohort 3 are reported.